Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Biomarker guidance allows patients 55 or older with low-grade luminal A-type bre...
Dr Timothy J. Whelan - McMaster University, Ontario, Canada
Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )
9 Jun 2022
Comment: Biomarker guidance allows patients 55 or older with low-grade luminal A...
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Comment: Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
7 Jun 2022
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patient...
Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio,...
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor ( Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
7 Jun 2022
Luminal A-type breast cancer patients with low levels of the Ki67 biomarker can ...
Dr Timothy J. Whelan - McMaster University, Ontario, Canada
Luminal A-type breast cancer patients with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )
7 Jun 2022
ASCO 2022: Panel discussion on bladder preservation
Dr Petros Grivas, Prof Rob Jones, Prof Phil Cornford and Prof Kurt Miller
ASCO 2022: Panel discussion on bladder preservation ( Dr Petros Grivas, Prof Rob Jones, Prof Phil Cornford and Prof Kurt Miller )
6 Jun 2022
Pembrolizumab demonstrates clinically meaningful improvement in distant metastas...
Dr Georgina Long - The University of Sydney, Sydney, Australia
Pembrolizumab demonstrates clinically meaningful improvement in distant metastasis-free survival in patients with melanoma ( Dr Georgina Long - The University of Sydney, Sydney, Australia )
6 Jun 2022
Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer wi...
Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San ...
Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients ( Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
6 Jun 2022
ASCO 2022: Latest in prostate cancer, including PARP inhibitors
Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford
ASCO 2022: Latest in prostate cancer, including PARP inhibitors ( Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford )
6 Jun 2022
Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of...
Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands
Neoadjuvant ipilimumab and nivolumab  immunotherapy could become new standard of care for resectable stage III melanoma ( Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands )
6 Jun 2022
Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer P...
Dr Pamela Kunz - Yale Cancer Center, New Haven, USA
Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer PFS than temozolomide alone ( Dr Pamela Kunz - Yale Cancer Center, New Haven, USA )
6 Jun 2022
ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal strom...
Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain
ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal stromal tumour ( Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
6 Jun 2022
FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-ty...
Dr Chiara Cremolini - University of Pisa, Pisa, Italy
FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )
6 Jun 2022